Bio-Rad Buys Bigger Stake in BioSource
After Firm Rejected Earlier Acquisition Offer
After BioSource International rebuffed Bio-Rad's unsolicited $82 million acquisition offer last week (see BCW 4/14/2005), Bio-Rad this week said it has increased its ownership in the reagents company to 6.8 percent from 5 percent.
Bio-Rad said in an SEC filing that it has purchased approximately $4.97 million worth of additional shares of BioSource common stock. In the filing, Bio-Rad stated that it believed "ownership of the shares could facilitate a business combination between [BioSource] and Bio-Rad."
"Our purchase of additional shares in BioSource further demonstrates our continuing interest in acquiring this company," Norman Schwartz, Bio-Rad's president, said in a statement. "Including these recent stock purchases, the average price for the shares we have acquired to date is still well below our $8.50 per share offer."
GE and Lilly Partner on Alzheimer's
Disease Diagnostics and Therapeutics
General Electric, through its global research unit and its GE Healthcare business, has inked a research collaboration with Eli Lilly for the discovery of diagnostics and therapeutics for Alzheimer's disease, the companies said this week.
According to the companies, the research collaboration will target beta-amyloid protein.
GE Healthcare will have access to Lilly's molecular libraries to search for compounds that might be used in targeted diagnostic imaging agents for Alzheimer's.
Lilly will subsequently have access to any diagnostic agents developed by GE to use in the discovery of Alzheimer's therapeutics, the companies said.
Agilent, Proteome Systems In Alliance;
Australia Cancer Center to Use Arrays
Agilent Technologies and Proteome Systems will collaborate on a combined platform for glycoprotein analysis, the companies said last week.
Under the terms of the agreement, Proteome Systems will make its GlycomIQ software compatible with Agilent's XCT, XCT Plus, and XCT Ultra ion-trap mass spectrometers, the companies said.
Financial terms of the deal were not disclosed.
The companies said that the combined products are expected to be available this summer. In addition, the companies will jointly develop applications and seminars as part of the marketing agreement.
GlycomIQ comprises kits, consumables, and informatics software for automated analysis of protein glycosylation.
Additionally, Agilent Technologies last week announced that researchers at Peter MacCallum Cancer Center of Melbourne, Australia, will use its comparative genomic-hybridization microarray products in a three-year cancer study.
The researchers will use the human CGH arrays to study mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.
Financial details were not disclosed.
NCI-Led Breast, Prostate Cancer Genotyping
Study to Use ABI's Technology, Protocol
The National Cancer Institute's Cohort Consortium will use genotyping technology and protocols from Applied Biosystems to study the genetics of breast and prostate cancer, ABI said last week.
The project, which combines six large prospective cohort studies that include more than 6,000 breast cancer and 8,000 prostate cancer patients, will make use of ABI's TaqMan SNP genotyping assays and 7,900HT real-time PCR systems to identify inherited gene variants that may contribute to the development of the two cancers. The SNP-genotyping assays were designed by ABI and will be made public to researchers.
Preliminary results from a first study by the Cohort Consortium started in 2003, entitled "Breast and Prostate Cancer and Hormone-Related Gene Variants Study," will be presented this week at the AACR meeting in Anaheim, Calif.
The NCI Cohort Consortium is a collaboration involving six American and European prospective cohort studies totaling 897,000 participants, three genomic facilities, and six genotyping centers.
Stratagene Licenses Gene Group IP
From Kimmel Cancer Center
Stratagene last week announced that it has exclusively licensed intellectual property held by the Sidney Kimmel Cancer Center of San Diego.
Under the terms of the agreement, Stratagene will get access to pending patents and related technology developed in the lab of Gennadi Glinsky and used to discover cancer-related genes. Stratagene will obtain exclusive rights to certain gene groups that have been shown to have predictive capabilities for cancer, particularly prostate, and breast cancers.
Financial terms of the agreement were not disclosed.
The company said it would use the IP to develop diagnostic tests based on its quantitative PCR technology.